The structure of the pharmaceutical market in Iran using concentration indices
Abstract
Background and objective: The efficiency and function of the pharmaceutical sector, as a vital portion of the health system, have a significant effect on intermediate and final indices of health. In this research, the structure of the pharmaceutical market in Iran was examined through the calculation of concentration indices in 2011.
Methods: In this cross-sectional study, the needed data was gathered from the Food and Drug Administration in the year 2011. Data were analyzed using SPSS software version 20 and Microsoft Office Excel software. Finally, two common measures of market concentration, the Concentration Ratio and the Herfindahl-Hirschman Index, were calculated.
Results: The largest and the smallest shares of the industry were 5.57% and 0.01%, respectively. The average industry share was 1.09%. The share range was calculated to be 5.56%. The Herfindahl-Hirschman Index was 248.5, which indicates a very low concentration of the pharmaceutical market in Iran. Also, based on the Concentration Ratio of 4 companies (18.39%), the concentration of the pharmaceutical market has been too low.
Conclusion: The pharmaceutical market in Iran has a very low concentration and it does not have an exclusive mode in terms of market structure. Therefore, it can be attributed to the competitive model. The policy makers in this area can use this characteristic as a leverage to improve efficiency, fairness, revenue and health indices.
References
Ebadi J, Ghavam MH. Allocation of Pharma Subsidies with Respect to Efficiency and Equality.
Tahghighate Eghtesadi. 2009; 44(86): 131-62.
Gellman B. A Turning Point That Left Millions Behind: Drug Discounts Benefit Few While Protecting
Pharmaceutical Companies’ Profits Series: DEATH WATCH: AIDS, Drugs and Africa; 2/3. Washington
Post: 2000.
Boseley S. Third World Dying for New Medicines. The Guardian. 2001.
WHO. WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy. 2000- 2003. Available From: http://apps.who.int/medicinedocs/pdf/whozip16e/whozip16e.pdf.
Cecilia Oh. TRIPS, Drugs and Public Health: Issues and Proposals. Malaysia: Third World Network; 2001.
Zhang JX, Tao J. DE1 Market Concentration and ITS Cross-Linkage With The Consumption of ACE
Inhibitors and Arbs. Value in Health. 2009; 12(7): A342. doi: 10.1016/S1098-3015(10)74683-0.
Dinarvand R. New National Drug Policy in Iran leading to Expanded Pharmaceutical Market and Extended
Access of Public to Medicines. Iranian J Publ Health. 2009; 38(Suppl 1): 158-61.
Economist Intelligence Unit. Asia Competition Barometer Pharmaceuticals. Singapore’s Economic
Development Board; 2012.
Curry B, George KD. Industrial concentration: A survey. The Journal of Industrial Economics. 1983; 31(3):
-55. doi: 10.2307/2097885.
Ebadifard Azar F, Rezapour A. Health Care Economics. Tehran: Ebadifard Publication; 2012; 107.
Rezaei F, Nasiri N, Haqiq H. An Empirical Analysis of Industry Concentration Efficacy in the Prediction of
Manufacturing Industries’ Stock Returns. Journal of Management Studies in Development & Evolution.
; 20(62): 61-89.
Mcpake B, Normand C. Health Economics. 2 ed. New York: Routledge; 2005; 143.
Santerre R, Neun S. Health Economics: Theories, Insights, and Industry Studies. Mason, OH: South- Western Cengage Learning; 2010.
Roberts MJ, Reich MR. Pharmaceutical Reform: A Guide to Improving Performance and Equity.
Washington, DC: World Bank; 2011. doi: 10.1596/978-0-8213-8760-3.
Zweifel P, Breyer F, Kifmann M. Health Economics. Springer; 2009.
Tsai YW, Wen YW, Huang WF, Kuo KN, Chen PF, Shih HW, et al. Pharmaceutical penetration of new
drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for
diabetes. Eur J Health Econ. 2010; 11(3): 279-90. doi: 10.1007/s10198-009-0174-1. PMID: 19649666.
Cameron A, Laing R. Cost savings of switching private sector consumption from originator brand
medicines to generic equivalents. Geneva: World health report; 2010.
Heikkonen T, Tamminen N. The Concentration of Pharmaceutical Market in Some Medicine Groups in
Finland. Value in Health. 2009; 12(7): 244-5. doi: 10.1016/S1098-3015(10)74195-4.
Torres Guerra S, Gutiérrez JP. [The pharmaceutical market in Mexico: size, value, and concentration]. Rev
Panam Salud Publica. 2009; 26(1): 46-50. doi: 10.1590/S1020-49892009000700007. PMID: 19814881.
Tahsiry A. Reform of Drug Pricing is important. Donyaye eqhtesad. 2012.
Chen Y, Schweitzer SO. Issues in Drug Pricing, Reimbursement, and Access in China with References to
Other Asia-Pacific Region. Value Health. 2008; 11 Suppl 1: S124-9. doi: 10.1111/j.1524- 4733.2008.00376.x. PMID: 18387056.
Bissonnette L, Wilson K, Bell S, Shah TI. Neighbourhoods and potential access to health care: The role of
spatial and aspatial factors. Health Place. 2012; 18(4): 841-53. doi: 10.1016/j.healthplace.2012.03.007.
PMID: 22503565.
Parikh P, Leigh S, Parikh R, Meng H, Sakellarios N, Brown D. Association of Financial Barriers to Health
Care With Access to Care, Quality of Care and Outcomes in Diabetics With Coronary Artery Disease. J
Am Coll Cardiol. 2012; 59(13): 1842. doi: 10.1016/S0735-1097(12)61843-9.
Roll K. The influence of regional health care structures on delay in diagnosis of rare diseases: The case of
Marfan Syndrome. Health Policy. 2012; 105(2-3): 119-27. doi: 10.1016/j.healthpol.2012.02.003. PMID:
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
